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ABSTRACT: According to the WHO, artemisinin-based combination
therapies (ACTs) have been integral to the recent reduction in deaths due to
Plasmodium falciparum malaria. ACT-resistant strains are an emerging problem
and have evolved altered developmental stages, reducing exposure of the most
susceptible stages to artemisinin drugs in popular ACTs. Lipophilicity, log Kow,
is a guide in understanding and predicting pharmacokinetic properties such as
terminal half-life which alters drug exposure. Consistent log Kow values are not
necessarily available for artemisinin derivatives designed to extend terminal half-
life, increase bioavailability, and reduce neurotoxicity. For other drugs used in
ACTs, an assortment of experimental and computational log Kow values are
available in the literature and in some cases, do not account for subtle but
important differences between closely related structures such as between
diastereomers. Quantum chemical methods such as density functional theory
(DFT) used with an implicit solvent model allow for consistent comparison of physical properties including log Kow and distinguish
between closely related structures. To this end, DFT, B3LYP/6-31G(d), with an implicit solvent model (SMD) was used to
compute ΔGowo and ΔGvowo for 1-octanol−water and olive oil−water partitions, respectively, for 21 antimalarial drugs: 12 artemisinin-
based, 4 4-aminoquinolines and structurally similar pyronaridine, and 4 amino alcohols. The computed ΔGowo was close to ΔGowo
calculated from experimental log Kow values from the literature where available, with a mean signed error of 2.3 kJ/mol and mean
unsigned error of 3.7 kJ/mol. The results allow assignment of log Kow for α-and β-diastereomers of arteether, and prediction of log
Kow for β-DHA and five experimental drugs. Linear least square analysis of log Kow and log Kvow versus terminal elimination half-life
showed strong linear relationships, once the data points for the 4-aminoquinoline drugs, mefloquine and pyronaridine were found to
follow their own linear relationship, which is consistent with their different plasma protein binding. The linear relationship between
the computed log Kvow and terminal elimination half-life was particularly strong, R
2 = 0.99 and F = 467, and can be interpreted in
terms of a simple pharmacokinetic model. Terminal elimination half-life for β-DHA and four experimental artemisinin drugs were
estimated based on this linear relationship between log Kvow and terminal t1/2. The computed log Kow and log Kvow values for epimers
α- and β-DHA and α and β-arteether provide physical data that may be helpful in understanding their different pharmacokinetics
and activity based on their different molecular geometries. Relative solubility of quinine and quinidine are found to be sensitive to
thermal corrections to enthalpy and to vibrational entropy and do not follow the general trend of longer terminal t1/2 with greater
predicted log Kow. Geometric relaxation of α- and β-DHA in solvent and inclusion of thermal correction for enthalpy and entropy
results in correct prediction that α-DHA is favored in aqueous environments compared to β-DHA. Predictions made regarding
experimental drugs have implications regarding their potential use in response to artemisinin drug-resistant strains.
■ INTRODUCTION
The World Health Organization, WHO, reported an estimated
219 million malaria cases with 435 thousand deaths in 2017
with most of these cases caused by the Plasmodium falciparum
species of malaria, the predominant species in sub-Saharan
Africa (99.7%), South East Asia (62.8%), the Eastern
Mediterranean (69%), and Western Pacific (71.9%).1 Accord-
ing to the WHO, nearly half the world’s population was at risk
of malaria in 2017 with 92% of cases and 93% of deaths taking
place in Africa and 87 countries with active malaria
transmission. Since 2010, malaria deaths per 100 thousand at
risk have declined worldwide.1 The WHO considers
artemisinin-based combination therapies, ACTs, as “integral
to the recent success of global malaria control”.1 The molecular
structure of artemisinin with ring conformations and junctions
determined by X-ray crystallography is shown in Figure 1. The
molecular structures of dihydroartemisinin, DHA, and other
artemisinin drugs used in ACTs are shown in Figure 2.
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According to Haldar et al. (2018), resistance has emerged to
all antimalarial drugs in wide clinical use.2 In most regions
where P. falciparum malaria is endemic, resistance to ACTs has
not been observed. As of 2019, for example, ACTs, in
particular artesunate + amodiaquine and artemether +
lumefantrine, are efficacious and safe in Cameroon.3 Resistance
differs from region to region. As of June 2019, artemisinin and
ACT-resistant malaria is well established near the Thai−
Cambodia border and spreading through the Greater Mekong
Sub-Region (GMS).4 Although ACTs typically have >95%
efficacy, from one to four ACTs now have >10% failure rates in
the GMS.1 Chloroquine-resistant malaria first emerged in the
GMS before spreading to Africa. Such a pattern if followed by
ACT resistance could be devastating. Better understanding of
how the structures and resulting physical properties of current
antimalarial drugs relate to their pharmacokinetics and
antimalarial activity can provide a useful guide for the
development of new drugs and drug therapies in the face of
antimalarial drug resistance.
Artemisinin drugs in widely used ACTs have shorter
elimination half-life and act quickly, eliminating most of the
parasite population and quickly alleviating symptoms, while
partner drugs with longer elimination half-life clear the
remaining parasite population and guarantee the therapeutic
outcome. Hott et al. (2015) found Cambodian F. falciparum
strains with partial resistance to artemisinin drugs to have an
extended ring stage and shortened trophozoite stage and
hypothesized that this reduces drug exposure during stages
when the parasite is most susceptible, elongates stages when it
is less susceptible, and allows for ring stage dormancy to be
triggered by DHA.5 These changes in parasite development
however show less resistance to DHA than to artemisinin and
artelinic acid, a drug never used clinically in the GMS. This
indicates possible resistance against the artemisinin family of
drugs rather than to specific artemisinin drugs.5 Chandra et al.
(2015) found regulation of glutathione with L-buthionine
(S,R)-sulfoximine to increase the efficacy against arteether-
resistant Plasmodium vinckei in mice, demonstrating a possible
strategy for prolonging the use of artemisinin drugs against
resistant strains.6 Hastings and Hodel (2014) note the use of
combination therapy to slow or prevent drug resistance and
argue for the importance of a pharmacological rather than a
purely genetic approach toward understanding drug resistance
as a basis for design of combination therapies and lowering
effects of toxicity.7 Hastings et al. (2016) argue the short half-
life of artemisinin drugs allow for their protection against
resistance by ACT partner drugs that kill artemisinin-resistant
strains but also leave the partner drugs as monotherapies
making them more vulnerable to resistance.8 Hasting et al.
(2016) discuss use of their pharmacological model to
investigate how ACT design may target developmental stages
of the malarial parasite.9 Perhaps artemisinin derivatives with
longer half-life can help to protect their ACT partners while
targeting parasite developmental stages more vulnerable to
artemisinin drugs. Although more lipophilic artemisinin
derivatives with longer elimination half-life offer greater
exposure time, arteether, as an example, is not used as widely
because it has slower absorption rates and higher risk of
neurotoxicity.10 Wesche et al. (1994) found neurotoxicity of
artemisinin drugs to be sensitive to substitution at C9 and C10
and found DHA and artesunate which rapidly converts to
DHA in vivo to have the greatest neurotoxicity.11
Design and synthesis of new artemisinin-based drugs has had
goals of increasing elimination half-life and bioavailability while
decreasing possible neurotoxicity. Avery et al. (2002), for
example, synthesized numerous C9 artemisinin derivatives and
used in vitro and in vivo rodent evidence to narrow to the two
most promising for drug development.12 Their molecular
structures, Avery-14 the most economical and Avery-17 the
most potent are shown in Figure 3.12 Bigucci et al. (2008)
Figure 1. Molecular structure of artemisinin with conformation of rings in the fused ring system and ring junctions as determined by X-ray
crystallography from the literature.
Figure 2. DHA and artemisinin derivatives with −OR substituents at C10.
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Figure 3. Artemisinin derivatives with substituents at C9.
Figure 4. 4-Aminoquinoline-based antimalarial drugs used in ACT and structurally similar pyronaridine also used in ACT.
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tested the bioavailability of two fluoroalkyl derivatives of DHA,
10β-(trifluoropropyloxy)dihydroartemisinin (F1-DHA), a C10
substituted compound shown in Figure 2, and 10-trifluor-
omethyl-16-[2-(hydroxyethyl)piperazine] (F2-DHA), a C9 and
C10 substituted compound shown in Figure 3.
13 They found
evidence that the fluoroalkyl ether substitution and C10 in F1-
DHA presents an obstacle for absorption across the intestinal
lining and discuss these results in the context of solubility and
their log Koct:Ringer values of 1.89 for artemisinin, 4.50 for F1-
DHA, and 2.55 for F2-DHA. Their log Koct:Ringer is lower than
log Kow for artemisinin reported by Haynes et al. (2006), 2.94
(experimental), and 3.17 (computational).14 Consistent lip-
ophilicity values where available allow for comparison of
pharmacokinetic properties on a consistent basis. Methods of
estimating log Kow values that allow for comparison on equal
footing of a wide range of drugs based on their molecular
structures can be a basis for estimating relative pharmacoki-
netic properties.
Computational approaches can, in some cases, quickly
estimate physical properties such as log Kow based on
molecular structures and be effective tools for screening of
potential drugs. Although widely used methods such as Clog
P15 based on molecular fragments and ALOGPS 2.116−18
based on computational neural networks can give quick results
with high accuracy, they do not distinguish between
diastereomers in their predicted log Kow values. Clog P, for
example, predicts quinine and quinidine to have the same log
Kow, whereas these two drugs are known to have different
pharmacokinetics, protein binding, and antimalarial activity.19
Zaera et al. (2009) using NOESY NMR methods and density
functional theory, DFT, computations found solubility differ-
ences between cinchona compound diastereomers to be
attributable to differences in vibrational entropy resulting
from a slight shift in the center of mass between
diastereomers.20 Quicker computational methods generally
do not allow for as detailed an understanding of physical
properties resulting from molecular structure. There may be a
range of log Kow values available in the literature for a given
compound and one may wonder which is most consistent with
the drugs biological behavior. Quantum chemical methods
such as DFT can be used with an implicit solvent model to
predict molecular structural properties in far greater detail and
with good accuracy but may become both impractical and less
accurate with larger (>50 atoms) molecules with more
rotatable bonds.21 Such computations, when applied appro-
priately however, can give a consistent approach toward
properties such as log Kow including subtle differences between
closely related compounds such as diastereomers and can
provide a consistent basis for understanding how structural
properties are related to physical properties and biological
behavior across a group of related compounds.
In this work, 21 antimalarial drugs from three families,
artemisinin-based (Figures 1−3), 4-amino quinoline and
structurally similar pyronaridine (Figure 4), and amino
alcohols (Figure 5), are studied using DFT, B3LYP, and an
implicit solvent model, SMD. Free-energy changes are
computed for transfer from water to 1-octanol, ΔGowo , and
from water to olive oil, ΔGvowo . The computed ΔGowo are
compared to ΔGowo calculated from experimental log Kow values
from the literature and errors examined to identify outliers.
The results allow log Kow for three sets of diastereomers to be
clarified and estimates of log Kow are made for five
experimental antimalarial drugs, β-DHA, and the α-and β-
diastereomers of arteether. Linear relationships between log
Figure 5. Quinolinemethanols quinine, quinidine, and mefloquine. Atom numbering for quinine and quinidine will be referred to in the Results and
Discussion sections.
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Kow and log Kvow and terminal elimination half-life are
examined for log Kow values computed using DFT and the
SMD solvent model, log Kow computed using ALOGPS version
2.1 online, and experimental log Kow from the literature. Linear
trends and statistical outliers are considered with regard to
drug family and protein binding. The strong linear relation-
ships that emerge can be interpreted using a simple
pharmacokinetic model and allow estimates of terminal
elimination half-life to be made for five experimental
antimalarial drugs. Computed dipole moments and computa-
tional results including geometry relaxation in the different
solvents allow some observed properties of diastereomers to be
understood in terms of their polarity and computed entropies
and enthalpies in different solvents.
■ METHODS
Geometry optimization of each drug was carried using the
B3LYP22−25 hybrid density functional with the 6-31G(d) basis
set and followed by vibrational analysis to confirm that a local
minimum of energy was found, that is, all positive real
vibrational frequencies. A first set of computations was carried
out by coauthors TDK and SK using Gaussian 09, Revision
B.0126 and then confirmed with corrections and revisions
where needed by JDA using Gaussian 16, Revision A.03.27
Input molecular structures for artemisinin and artemisinin
derivatives were carefully checked to have ring conformations,
ring junctions, and conformations as indicated by X-ray
structures.28−30 Piperaquine is known to have a number of
thermally accessible conformers at room temperature.31 After
making computations on several piperaquine conformers, a
conformer similar to that displayed as the 3D geometry on
PubChem was found to have the lowest in energy of those
considered.32 Interestingly, results from implicit solvent
models including SMD are not significantly improved going
from a single conformation approach to one involving an
ensemble of conformations.21 It is common practice to use
implicit solvent models with a single molecular conforma-
tion.33 The assumption in doing this is that differences in the
vacuum and solvated distribution of conformers are negligible
and have negligible enthalpic and entropic effects on the
solvent.33 In this work, we use a single conformation
methodology. An effort was made to use lowest energy
conformations as supported by the literature but global energy
minimum were not methodically searched. Quinine and
quinidine are also known to have several thermally accessible
conformers at room temperature. Experiment indicates that a
cis-γ-open conformer is lowest in energy and this conformation
was chosen for DFT geometry optimization in this work.34
Optimized gas phase geometries confirmed as local energy
minima with all positive real vibrational frequencies were then
used for calculations with the SMD35 solvent model also at the
B3LYP/6-31G(d) level of theory. Examples for which
experimental geometries were not found in the literature, the
global minimum in energy conformation was assumed to be
one matching qualitative steric reasoning and in some cases,
geometries of several conformers were computed to find the
lowest in energy of those considered. In the remainder of this
paper, B3LYP/6-31G(d) computations with the SMD solvent
model will be referred to as DFT for in vacuo computations
and DFT-oct or DFT-olive according to the solvent being
modeled. SMD solvent descriptors for water were those
included with Gaussian 09 and Gaussian 16. Those for olive oil
were added to input files manually and are shown in Table
1.36,37 It was found that the 1-octanol parameters from the
Minnesota Solvent Descriptor Database38 lead to a systematic
error of about 11 kJ/mol, underestimating solubilities in 1-
octanol compared to water when used with G09 and G16
implementations of SMD, whereas use of the scrf = (SMD,
solvent = n-octanol) command to utilize built-in parameters
for 1-octanol removed this systematic error.
Partitioning of a solute between solvents depends on the
relative thermodynamic stability of the solute in each solvent at
constant temperature and pressure and therefore the difference
in Gibbs free energy of the solute in each solvent, in this case,
Δ = −G G Gowo organico watero (1)
Gorganic
o and Gwater
o can be approximated using methods of
quantum chemistry and an implicit solvent model. log Kow may
then be calculated according to
= −ΔK G
RT
log
ln(10)ow
ow
o
(2)
Values of log Kow for 1-octanol−water partitions and log
Kvow for olive oil−water partitions from computational results
were calculated by eqs 1 and 2. Equation 2 was likewise used to
convert log Kow values from the literature to ΔGowo to compare
with the computed ΔGowo . The computational neural network
program ALOGPS 2.118 accessed online16,17 was used to
compute log Kow values in two ways that in some cases gave
different results: (1) using the SMILES descriptor found on
PubChem32 and (2) using the DFT-optimized geometry in
.mol2 format.
A second aspect of this work was the comparison of
computed log Kow values and those from the literature to
terminal elimination half-life. An effort was made to use
consistent terminal elimination half-life, that is, healthy adult
human subjects given oral dosage not in combination with
other drugs and not after repeated dosing. When terminal
elimination half-life for human subjects were not available,
those for rats were converted to estimated elimination half-life
for humans.39 Literature log Kow values were experimental
where available but otherwise, computed estimates available in
the literature were used and software specified.
The terminal elimination half-life is defined as the time
required for the blood plasma concentration of the drug to
decrease by half after a pseudo-equilibrium (steady-state)
distribution has been reached.40 This definition in terms of a
pseudo-equilibrium property is the basis for expecting a clear
relationship between terminal t1/2 and log Kow which is based
Table 1. Olive Oil Solvent Descriptors Used in Implicit
Solvation Computationsa
descriptor olive oilb
Eps 3.109
EpsInf 2.155
HBondAcidity 0.19
HBondBasicity 0.45
SurfaceTensionAtInterface 32.80
CarbonAromaticity 0.0
ElectronegativeHalogenicity 0.0
aDescriptors are designated according to their keywords in Gaussian
software. bChamberlin et al. (2008) and private communication with
Gaussian technical support.
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on ΔGowo . In cases for which the simplest one-compartment
pharmacokinetic behavior applies, the terminal elimination
half-life is based on the unbound steady-state distribution
volume, Vd,ss,u, and the unbound clearance, CLu.
= =t
V
kCL
ln(2)
ln 2
1/2
d,ss,u
u (3)
Vd,ss,u is the volume required to contain the total steady-state
amount of the drug at concentration equal to its steady-state
unbound blood concentration, and CLu is a proportionality
constant relating the rate of elimination to the total amount of
drug in circulation.41
The rate constant, k, is for the overall terminal stage first-
order process of elimination. Broccatelli et al. (2018) identify a
selection of terminal half-life efficient molecular structural
modifications which increase both Vd,ss,u and CLu with
lipophilicity.41 Where one value of k is appropriate for a series
of drugs, a consistent value for Vd,ss,u/CLu is implied.
We use a simple pharmacokinetic model to interpret linear
relationships between terminal t1/2 and log Kow. The drug in a
lipophilic environment is Do, in an aqueous environment, Dw,
and the drug after a rate-determining elimination process step
is Delim. According to the definition of terminal elimination
half-life, Dw has a steady-state concentration, [Dw]. According
to the simplest possible pharmacokinetic model, elimination in
the terminal phase is first order.
⎯ →⎯⎯⎯D D
k
Do w
elim
elimV (4)
with [Do] ≈ [D] for highly lipophilic drugs, elimination from
the aqueous phase is much slower than equilibration of the
drug between lipophilic and aqueous environments, and using
the steady-state approximation
≈ − [ ] ≈ −
− +
[ ]
≈ −
− +
= −
+
Δ
Δ
( )
( )
k
K
D
k
D
k
k k
K
Rate
1
and
1 (ln(10)log 1)
G
RT
G
RT
elim
ow
elim
elim elim
ow
ow
o
ow
o
(5)
Substituting k into the expression for t1/2 from first-order
kinetics
= = +
i
k
jjjjj
y
{
zzzzzt k k
K
k
ln 2 ln(2)ln(10)
log
ln 2
1/2
elim
ow
elim (6)
In cases where this linear relationship between t1/2 and log
Kow holds, we expect slope = ln(10) × intercept and kelim in the
context of this simple model to be kelim=(ln(2)ln(10))/slope.
Linear least squares analysis and 95% certainty ranges were
calculated using the LINEST function from MS-Excel and
predictions of log Kow and terminal elimination half-lives for
experimental drugs were made according to eq 7 with student
t0.95,n−2 from MS-EXCEL
42 Unless stated otherwise, computed
error ranges are 95% certainty ranges.
̂ + ̂ ± + +
− ̅
−mx b t s n
x x
SS
( ) 1
1 ( )
n xy
xx
p 0.95, 2
p
2
(7)
Outliers in plots of log Kow versus terminal elimination half-
life were identified according to their standardized residuals,
ei*, calculated according to eq 8, where ά is the standard error,
ei is residual for point i, and hi is leverage.
∑
σ
* =
̂ −
= + − ̅
= − ̅
e
e
h
h
n
x x
SS
SS x x
1
where
1 ( )
and
( )
i
i
i
i
i
xx
xx
i
i
2
2
(8)
Standardized residuals for outliers were typically several
times greater than those for other data points and consistent
across regressions using all sources of log Kow. Outliers were
most clearly distinguished for the log Kow from DFT-oct and
because our focus was the application of this method, these
data were used to select outliers where there was less
distinction using other sources of log Kow.
■ RESULTS
Accurate optimized geometries are important to results that
follow, hence, comparison to literature geometries are
presented first. To evaluate the accuracy and systematic errors
in computed transfer free energies, ΔGowo , computed values
were compared to those calculated from the literature, that is
log Kow values, and the mean signed error was found to be 2.3
kJ/mol. Several compounds were found to have errors outside
of a 99.9% certainty range and these outliers will be discussed
later. Computed and literature log Kow values were compared
to the terminal elimination half-life from the literature, outliers
identified, and terminal elimination half-lives estimated for the
experimental drugs and for β-DHA.
Accuracy of Computed Geometries. The endoperoxide
linkage is known to be a requirement for the antimalarial
activity of artemisinin drugs. Its bond lengths, angles, and
torsional angle are sensitive to correct ring conformations, so
comparison of these to experimental values is evidence of
correct computed geometries. Endoperoxide bond lengths and
angles for artemisinin, β-arteether, and β-DHA are compared
to those from X-ray crystal structures from the literature in
Table S1 in the Supporting Information and show strong
agreement. Endoperoxide bond lengths and angles for α-
arteether and α-DHA are also included. To our knowledge, X-
ray structures for α-DHA have not been reported in the
literature. These bond lengths and angles are close to those for
β-arteether and β-DHA, perhaps indicating that differences in
antimalarial activity are not due to chemical reactivity of the
endoperoxide group but to differences in physical properties
such as lipophilicity.
Bond lengths and angles for optimized geometries of the
most stable conformer for quinine and quinidine, cis γ open
(3), match those for similar computations in the literature for
these drugs, which is in agreement with NMR studies in
solution. The torsional angles given in Table S2 are most
relevant to this lowest energy conformation. Also see the atom
numbering scheme for quinine and quinidine in Figure 5.
Computed ΔGowo Compared to ΔGowo Based on the
Literature log Kow. Comparison of ΔGowo computed using
DFT-oct to ΔGowo calculated from the literature log Kow values
using eq 2 gives an indication of the accuracy of these
computations (see Table 2). The ΔGowo values DFT-oct are
mostly not as negative as those calculated from log Kow from
the literature, that is, they underestimate solubility in 1-octanol
compared to water. Mean unsigned errors expected from the
use of the SMD solvent model vary with the functional
group.35 For example, for SMD used with B3LYP/6-31G(d),
water−organic transfer free energies for aromatic N-hetero-
cycles and bifunctional H, C, N compounds are 3.0 and 3.6 kJ
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mol−1, respectively.35 The mean unsigned error for the results
in Table 2 is 3.7 kJ mol−1. Piperaquine, amodiaquine, and
lumefantrine R and S enantiomers have errors that do not fall
within a 99.9% certainty range and will be discussed later.
Predicted log Kow for experimental antimalarial drugs and for
diastereomers for which assignment of log Kow, to our
knowledge, is not available, are shown in Table 3. The log
Kow for artelinic acid has been predicted using other
computational methods; BioLoom gives 4.51,46 PubChem52
gives an XLogP3-AA53 value of 4.1, and ALOGPS 2.1 gives
3.79 when artelinic acid’s SMILES descriptor is used as input
and 2.06 when artelinic acid’s DFT-optimized geometry is
submitted in .mol2 format (see Table 4). Experimental and
computed log Kow reported in the literature do not distinguish
between α- and β-isomers of arteether (see Table 4). The α-
and β-isomers of arteether and DHA have different
pharmacokinetics and antimalarial activity reflecting their
different structures and different lipophilicity. The log Kow
for individual isomers may accordingly be useful. Predictions of
these are in Table 3.
Comparison to Terminal Elimination Half-Life. Com-
puted and literature, log Kow and log Kvow, values are compared
with elimination half-life for each drug in Table 4. Terminal
elimination half-life was not available for β-DHA, F1-DHA, F2-
DHA, Avery 14, and Avery 17. Amodiaquine is quickly
converted in vivo to desethyl amodiaquine, so, elimination half-
life given for it is either short and reflects this chemical
conversion or long and reflects the pharmacokinetics of
desethyl amodiaquine.59 Artesunic acid in vivo is quickly
hydrolyzed to DHA.59 Artemether’s steady-state plasma levels
reflect its rapid conversion to DHA in patients and healthy
subjects dosed orally.56 The steady-state plasma concentrations
of arteether, on the other hand, are high compared to its
metabolite DHA.66 Amodiaquine, artesunic acid, and arte-
mether have steady-state plasma concentrations reflecting their
relatively fast chemical conversion and therefore their log Kow
values cannot be expected to be as good an indicator of their
terminal elimination half-life as drugs that are either converted
to their metabolites less rapidly or to a lesser extent.
Amodiaquine, artesunic acid, and artemether are therefore
not included in the linear least squares analysis to be discussed
next.
Linear least square regressions of log Kow from DFT-oct, log
Kow (lit), log Kow from ALOGPS 2.1, and log Kvow from DFT-
olive versus elimination half-life were made. Omission of worst
outliers for the log Kow from DFT-oct versus terminal
elimination half-life regressions for each consecutive regression
resulted in statistical outliers being removed in the following
order: piperaquine, pyronaridine, mefloquine, chloroquine, and
desethyl amodiaquine. Piperaquine was a strong outlier
regardless of the source of log Kow. Subsequent choice of the
worst outlier was not necessarily clear for log Kvow (olive oil−
water) regressions; however, the compounds omitted based on
log Kow regressions also improved the olive oil−water log Kvow
linear fits markedly. The compounds omitted were all
quinoline-based antimalarial drugs and pyronaridine which
has strong structural similarities to the quinoline-based drugs.
It is interesting that quinine and quinidine have much different
elimination half-life than the other quinoline-based drugs. The
remaining drugs were artemisinin-based drugs, quinine and
quinidine, and lumefantrine, that is, artemisinin drugs and
amino alcohols. Linear regression results for the remaining ten
compounds, artemisinin, α-DHA, β-DHA, α-arteether, β-
arteether, artelinic acid, quinine, quinidine, and R and S
enantiomers of lumefantrine are shown in Table 5.
The computed log Kvow for olive oil−water partitioning have
the strongest linear relationship with terminal elimination half
-life for this subset of compounds and the relationship between
slope and intercept is close to the prediction based on the
simple kinetic model presented in the Methods section. The
certainty range for the slope, 9.21−10.97, is within the 95%
certainty range of the intercept multiplied by ln(10), that is
1.04−17.15 h. Calculated from the slope, kelim = 0.158 ± 0.014
h−1. The plot and best fit line are shown in Figure 6. Figure S1
in the Supporting Information includes log Kow from the lit.,
DFT-oct, DFT-olive, and ALOGPS 2.1 with SMILES input
versus terminal t1/2 and individual trend lines for each method,
and lumefantrine data is included.
The strong linear relationships found between log Kow from
DFT-oct and terminal elimination half-life for these drugs
Table 2. ΔGowo from DFT-oct Compared to ΔGowo Calculated
from the Literature log Kow Values (kJ mol
−1)
drug ΔGowo (DFT-oct) ΔGowo (lit)
artemisinin −12.29 −16.782a
α-DHA −12.03 −13.414a
β-DHA −14.46 −15.583a
artemether −18.50 −20.149b
α-arteether −19.53 −22.204c
β-arteether −21.91 −22.204c
artesunic acid −10.74 −15.811a
artelinic acid −19.88 −25.743d
F1-DHA −25.80 −25.686e
F2-DHA −18.38 −14.555e
amodiaquine −17.64 −24.316f
desethyl amodiaquine −14.90 −18.894f
piperaquine −24.71 −33.106g
chloroquine −22.83 −26.942f
quinine −11.53 −15.069h
quinidine −12.12 −16.441h
mefloquine −18.85 −22.261i
lumefantrine-R −53.21 −47.605j
lumefantrine-S −51.47 −47.605j
pyronaridine −24.96 −28.426k
aHaynes et al. (2006).14 bAvery et al. (1995).43 cRamu and Baker
(1995),44 Singh and Chaudhary (2006).45 dAbraham and Acree
(2013).46 eBigucci et al. (2008).13 fWarhurst et al. (2003).47 gPublic
assessment report (2011).48 hWarhurst et al. (2003)19 reporting
values from Tsai et al. (1993). iStrauch et al. (2011).49 jWahajuddin
et al. (2014).50 kCrowe et al. (2006).51
Table 3. Predicted log Kow Values Based on ΔGowo from
DFT-oct
drug predicted log Kow
artelinic acid 3.48
Avery-14 5.92
Avery-17 5.69
F1-DHA 4.52
F2-DHA 3.22
α-DHA 2.11
β-DHA 2.53
α-artheeter 3.42
β-artheether 3.84
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allow terminal elimination half-life for experimental artemisinin
drugs to be estimated. See Table 6.
When log Kow values for quinoline-based drugs and
pyronaridine are compared to their terminal elimination half-
life, the resulting relationships are not nearly as strong.
Piperaquine has an exceptional standardized deviation for the
linear least squares analysis using computational log Kow but
not the literature log Kow, and this is reflected in the higher R
2
and F values when the literature log Kow values are used. For
piperaquine, desethyl amodiaquine, quinine, quinidine, me-
floquine, chloroquine, and pyronaridine, log Kow values from
DFT-oct and from the literature show a stronger linear
relationship than log Kow from ALOGPS 2.1 and log Kvow from
Table 4. log Kow and log Kvow from DFT-oct, log Kow (Lit), ALOGPS 2.1, and Elimination Half-Lives for Healthy Adult
Subjects
compound log Kow (DFT-oct) log Kow (lit.
a) log Kow (ALOGPS 2.1
b) log Kow (ALOGPS 2.1
c) log Kvow (DFT-olive) t1/2 (h)
artemisinin 2.26 2.94 2.52 1.23 0.489 2.6e
α-DHA 2.11 2.35 2.25 0.86 −0.483 1.86e
artemether 3.24 3.53 3.02 1.48 1.56 3.10g
α-arteether 3.42 3.89 3.52 1.94 1.45 13.24h
β-arteether 3.84 3.89 3.52 1.94 2.196 30.17h
artesunic acid 1.88 2.77 2.35 0.93 −1.56 0.70i
artelinic acid 3.48 4.51d 3.79 2.06 1.197 15.63i
amodiaquine 3.09 4.26 4.83 4.83 0.621 5.3j
desethyl amodiaquine 2.61 3.31 3.96 3.96 0.396 240j
piperaquine 4.33 5.8 5.53 5.53 2.620 792k
chloroquine 4.00 4.72 5.28 2.72 304l
quinine 2.02 2.64 2.82 2.82 0.207 12.34m
quinidine 2.12 2.88 2.82 2.82 0.363 6.09p
mefloquine 3.30 3.90 3.10 3.10 1.09 334n
lumefantrine (R/S) 9.32/9.02 8.6 8.34 8.34 8.176 86o
pyronaridine 4.37 5.78 5.78 2.246 397f
aSee references for ΔGowo (lit.) given in Table 2. bIsomeric SMILES identifier submitted to ALOGPS 2.118 accessed on 10 October 2019 and before
through http://www.vcclab.org/web/alogps/. cB3LYP/6-31G(d) optimized geometry in .mol2 format submitted to ALOGPS 2.118 accessed
through http://www.vcclab.org/web/alogps/ on 10 October 2019 and earlier. dCalculated value BioLoom and presented in Table 2 of Abraham
and Acree (2013). eMedhi et al. (2009).54 fJittamala et al. (2015).55 gBangchang et al. (1994).56 hSabarinath et al. (2005).57 iCalculated from t1/2
rat data from Si et al. (2007)58 using eq 6 in Table 1 in Sarver et al. (1997). jOrrell et al. (2008).59 kTarning et al. (2005).60 lMoore et al. (2011).61
mBabalola et al. (1997).62 nStauch et al. (2011). oNosten and White (2007),63 Lefev̀re and Thomsen (1999): 71.3 h (fed) 35.1 h (fasted) Lefev̀re
and Thomsen (1999).64 pOchs et al. (1978).65
Table 5. Artemisinin-Based Drugs and Amino Alcohol
Linear Least Square Results for Computed and Literature
log Kow vs Terminal Elimination Half-Life from the
Literaturea
method slope intercept R2 F
log Kow DFT-oct 11.5 ± 0.7 −20 ± 3 0.978 309
log Kvow DFT-olive 10.1 ± 0.5 4 ± 2 0.985 467
log Kow ALOGPS 2.1 SMILES
input
13.9 ± 0.9 −31 ± 4 0.975 268
log Kow ALOGPS 2.1.mol2
input
12 ± 1 −10 ± 5 0.924 85
log Kow literature 14 ± 1 −30 ± 6 0.947 124
aSlopes and intercepts are given with their standard deviations.
Figure 6. log Kvow from DFT-olive vs terminal elimination half-life. The best fit line includes lumefantrine R and S data points which are not shown
to improve clarity.
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DFT-olive. See Table 7. The relationship between slope and
intercept for log Kvow versus terminal t1/2 is closer to what one
would expect based on eq 6, in the Methods section, than for
log Kow versus t1/2. The certainty range for the slope, 110−250
h is within the certainty range of the intercept multiplied by
ln(10), −160 to 390 h. Calculated from the slope, kelim = 0.014
± 0.012 h−1.
■ DISCUSSION
Outliers. The compounds found to be outliers need to be
considered and explained in the context of the methods used.
The DFT-oct transfer free energies, ΔGow, for piperaquine,
amodiaquine, and lumefantrine R and S enantiomers have
errors in comparison with ΔGow calculated from experimental
log Kow outside the 99.9% certainty range of errors for the
compounds considered in this work. Kolaŕ ̌ et al. (2013)
recognized two reasons for the failure of implicit solvent
models including SMD: (1) problematic functional groups and
(2) the molecule is large and flexible.21 Piperaquine,
lumefantrine, and amodiaquine have similar functionality as
the other compounds. Piperaquine and lumefantrine are the
largest molecules studied here with 69 and 67 atoms,
respectively, and with 6 and 9 rotatable21 bonds. Amodiaquine
with 47 atoms and 5 rotatable bonds is structurally and
functionally similar to desethyl amodiaquine with 41 atoms
and 4 rotatable bonds, which falls within the certainty range
indicating the larger error for amodiaquine to be due to its
greater number of atoms and rotatable bonds. It may be
tempting according to qualitative notions of conformational
entropy to estimate improved ΔGow based on the number of
known stable conformers but attempts to improve SMD
through an ensemble of conformers has been shown to not
lead to marked improvement.21 Perhaps this is because the
inclusion of entropic effects in implicit solvent models is not
well defined in terms of effects known to influence entropy in
explicit solvation models. Although the outliers in comparison
to ΔGow from DFT-oct give insight into the applicability of the
SMD model, outliers in the linear regression of log Kow versus
terminal t1/2 reflect differences in in vivo behavior of the drugs
considered.
The outliers identified in the plots of log Kow versus terminal
elimination half-life served to identify two different linear
relationships between log Kow and terminal t1/2, one involving
artemisinin drugs, amino alcohols (excluding mefloquine), and
lumefantrine and the other involving 4-amino quinolines,
mefloquine, and pyronaridine (see Figure 7). The trend lines
shown in Figure 7 both include quinine and quinidine. To
Table 6. Estimated Terminal Elimination Half-Life (h) for
Experimental Artemisinin-Based Antimalarial Drugs
Calculated from Linear Regression Results Presented in
Table 5
regression β-DHA Avery-14 Avery-17 F1-DHA F2-DHA
log Kow
DFT-oct
9 ± 11. 48 ± 11 46 ± 11 32 ± 11 17 ± 11
log Kvow
DFT-olive
6 ± 9. 48 ± 9 45 ± 9 30 ± 8 10 ± 9
log Kow
ALOGPS
2.1a
1 ± 12 53 ± 12 42 ± 12 22 ± 12 5 ± 12
log Kow
ALOGPS
2.1b
0 ± 21 60 ± 20 49 ± 20 20 ± 20 12 ± 19
log Kow
literature
7 ± 17 31 ± 16 4 ± 16
aSMILES strings translated by Online SMILES Translator and
Structure File Generator https://cactus.nci.nih.gov/translate/67 from
PDB files generated using GaussView software from optimized
geometries. bWith optimized geometries from DFT in .mol2 format.
Table 7. Quinoline-Based Drugs and Pyronaridine Linear
Least Square Results for Computed and Literature log Kow
vs Terminal Elimination Half-Life from the Literaturea
method slope intercept R2 F
log Kow DFT-oct 220 ± 70 −400 ± 200 0.712 14
log Kvow DFT-olive 180 ± 70 50 ± 120 0.598 7.4
log Kow ALOGPS 2.1
SMILES input
150 ± 60 −340 ± 260 0.57 6
log Kow literature 210 ± 40 −550 ± 160 0.86 31
aSlopes and intercepts are given with their standard deviations.
Figure 7. log Kow from DFT-oct vs terminal t1/2 with two linear relationships shown identified by analysis of outliers.
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understand the difference between these two groups of
compounds, it is useful to consider protein binding.
Differences in Protein Binding. The result that
artemisinin and amino alcohol drugs trend together for log
Kow versus terminal elimination half-life and quinoline drugs
trend together may be due to differences in protein binding
and, in the case of chloroquine, a larger distribution volume.
Piperaquine does not trend with artemisinin and amino
alcohol drugs in log Kow versus terminal elimination half-life
even when experimental log Kow values from the literature are
used, but it is not an outlier when only quinoline drugs are
compared. This may be due to the strong binding of quinoline
compounds to α1-acid glycoprotein. Piperaquine is more than
99% bound by plasma proteins and has 8 times more binding
to α1-acid glycoprotein than to human serum albumin.
68
Lumefantrine, in contrast, binds primarily to high-density
lipoproteins, HDL.69 Quinoline-based antimalarial drugs,
amodiaquine, primaquine, tafenoquine, quinacrine, and me-
floquine have high binding to α1-acid glycoprotein with
binding constants in the range of Ka = 10
5 to 106.70
Interestingly, chloroquine, unlike the other 4-aminoquinoline
drugs, is not found to bind significantly with α1-acid
glycoprotein.70 Ofori-Adjei et al. found (+) and (−)
enantiomers of chloroquine to be 34.5 and 47.5% bound to
α1-acid glycoprotein, respectively.
71 Chloroquine’s long
terminal elimination half-life is not due to high plasma protein
binding but to its large apparent distribution volume.72 Amino
alcohols, quinine, and quinidine bind less strongly to α1-acid
glycoprotein than mefloquine which is also an amino alcohol;
quinine’s α1-acid glycoprotein binding constant is Ka = 9.12 ±
0.73, and it is 85−95% protein bound, whereas quinidine is
70−80% protein bound.73 Mefloquine is 98% protein bound in
both patients and healthy volunteers,49 in accordance with its
greater dipole moment and its strong binding to α1-acid
glycoprotein.70,74,75
Quinine and quinidine trend with both artemisinin drugs,
including lumefantrine, and with other quinoline drugs perhaps
due to their similar plasma protein binding to artemisinin-
based drugs. DHA protein binding is higher in plasma from
patients (93%), than in healthy volunteers (88% Vietnamese
and 91% Caucasians).76,77 It is typical for α1-acid glycoprotein
levels to be higher in malaria patients than healthy subjects.
Artesunic acid is 73−81% protein bound in rats and humans.78
Artemether is 95−98% protein bound but only 33% bound to
α1-acid glycoprotein.
69 Terminal phase plasma concentrations
of artemether are accompanied by its metabolite, DHA.56 This
indicates that artemether’s terminal elimination half-life not
only depends on its lipophilicity and protein binding but its
chemical conversion to DHA. Arteether was found to be 73.4−
81.8% in 11 healthy male subjects with about 20 times greater
binding affinity to α1-acid glycoprotein than to albumin.
79
When log Kow is plotted against elimination half-life,
lumefantrine, quinine, quinidine, and the artemisinin-based
drugs trend together. This is likely due to stronger binding of
the 4-aminoquinoline drugs primarily to α1-acid glycoprotein
and, in the case of chloroquine, large distribution volume.
Lumefantrine, although highly fat soluble, does not trend with
the 4-aminoquinoline drugs because it binds primarily to high-
density lipoproteins.
Terminal Elimination Half-Life Versus log Kvow. The
linear relationship between terminal elimination half-life and
log Kvow for artemisinin drugs, quinine and quinidine, and
lumefantrine, is particularly strong, R2 = 0.985 and F = 467
(see Table 5). The slope and intercept follow the relationship
expected according to the simple kinetic model presented in
the Methods section, intercept × ln(10) = slope, and this is not
the case for the other log Kow versus t1/2 regressions in Table 5.
An elimination rate constant, kelim, in the context of this model
can be computed based on the slope and/or intercept.
Although all of the slopes in Table 5 make similar predictions
for kelim, the plot of log Kvow and t1/2 is the only one with an
intercept that seems meaningful. Perhaps the strong linear
relationship and agreement between the intercept and
pharmacokinetic model are evidence that predictions made
regarding solubility in olive oil, which is a biological fat, are
more relevant for comparison to in vivo properties, such as
terminal elimination half-life. The results are analogous for log
Kvow and t1/2 for the quinoline compounds but the linear fit is
much weaker, so the computed kelim has a much wider certainty
range. Equation 6 and the simple pharmacokinetic model from
which it is derived indicated two contributing factors to
terminal half-life, the hydrophobic/hydrophilic partitioning of
the drug and the rate of elimination of the drug from aqueous
environment. The rate constant, kelim, is for the elimination
from aqueous environment. It is predicted to be smaller for
quinoline drugs, and this may be due to different renal and
hepatic elimination processes and their greater plasma protein
binding in particular to α1-acid glycoprotein which does not
have a strong linear correlation with lipophilicity.75
Lumefantrine, log Kow, and Bioavailability. There is a
wide range of terminal elimination half-life values reported for
lumefantrine in the literature.80 Lefev̀re and Thomsen (1999)
find the lumefantrine terminal elimination half-life to be 71.3 h
(fed) and 35.1 h (fasted) and that lumefantrine’s bioavailability
increases 16 times when it is administered in conjunction with
food.64 Piperaquine by contrast shows little change in terminal
elimination half-life depending on whether subjects are fed or
fasted.81 Lumefantrine’s high predicted log Kow and log Kvow
are suggestive of lumefantrine’s solubility with dietary fats
which helps to increase its terminal elimination half-life and
strong binding to HDL proteins.
Diastereomers. The diastereomers α- and β-arteether have
different physical and pharmacokinetic properties and slightly
different antimalarial activity. To our knowledge, different log
Kow values for α- and β-arteether are not available in the
literature. The greater predicted log Kow for β-arteether
compared to α-arteether, 3.84 compared to 3.42 (Table 3),
is consistent with the terminal elimination half-life of 31.17 h
for β-arteether and 13.24 h for α-arteether.57 The greater
lipophilicity of β-arteether is understandable according to its
smaller dipole moment, 1.79 D compared to 2.84 D for α-
arteether, both computed using DFT. This difference in dipole
moment can be understood according to the difference in
geometry. The C10 ethyl ether in β-arteether points in the
opposite direction to the endoperoxide partially canceling the
molecular dipole moment (see Figure 8). The influence
between the orientation of C10 substituents with respect to the
endoperoxide group in artemisinin drugs and dipole moment
and the correlation of this with greater neurotoxicity with
smaller dipole moment was pointed out by Bhattacharjee and
Karle (1999).82
The α- and β-diastereomers of arteether have similar
antimalarial activity against strains of Plasmodium berghei in
rodents but slightly different activity depending on the strain
with β-arteether being slightly more active.83 β-arteether is also
found to be slightly more active against Plasmodium cynomolgi
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malaria in monkeys, whereas β-arteether and α/β-arteether
(30:70) mixture have similar activity against P. falciparum
malaria in humans and similar toxic side effects during
therapy.84 The slightly greater activity of β-arteether may be
due to its greater lipophilicity and smaller dipole moment
allowing it to pass through the erythrocyte cell membrane
more effectively, assuming it has not already been converted to
its metabolite, DHA.19
DHA is the active metabolite of some of the most widely
used artemisinin-based antimalarial drugs. Artesunic acid is
converted to the active metabolite, DHA most quickly
followed by artemether and then arteether. The pharmacoki-
netics, antimalarial activity, and toxicity of DHA are therefore
relevant to the behavior of the most widely used artemisinin
derivatives. Diastereomers, α- and β-DHA, interconvert in
solution and so, the properties of each are important to
consider. Haynes et al. (2006) report log Kow of the two DHA
epimers in solution to be 2.35 and 2.73 but do not specify the
respective values for α and β-DHA.14 According to DFT-oct,
log Kow = 2.11 for α-DHA and 2.53 for β-DHA, which is
evidence that the more lipophilic log Kow found by Haynes et
al. corresponds to β-DHA, consistent with its smaller dipole
moment, 1.582 D, compared to 3.147 D for α-DHA, according
to DFT.
DHA has a labile stereocenter at C10. D’Acquarica et al.
(2010) report that solid-state DHA consists of β-DHA only,
whereas α- and β-DHA interconversion rates in solution
depend on buffer, pH, and solvent polarity.85 They report that
the Gibbs free energy of activation for HPLC on-column
epimerization from α-DHA to β-DHA, ΔGα→β⧧,o , is slightly
higher than the reverse, ΔGβ→α⧧,o , based on van’t Hoff plots and
find the difference to be entropic which they believe suggests a
ring-opening mechanism.85 These relative free energies of
activation imply higher concentrations of α-DHA than β-DHA
at equilibrium, which is found to be the case in 50% v/v
ethanol/water solution and 50% v/v acetonitrile/water
solution.76 Batty et al. (2004) found plasma α-DHA/β-DHA
ratios in vivo to favor α-DHA of 6.3 ± 0.9 in patients with
falciparum malaria, 6.9 ± 0.8 in patients with vivax malaria, 6.9
± 0.6 in healthy Vietnamese volunteers, and 5.4 ± 0.8 in
healthy Caucasian volunteers.76 The greater dipole moment of
α-DHA may imply it to be more strongly bound to α1-acid
glycoprotein.75 If α-DHA has higher protein binding, more
unbound α-DHA would be formed from unbound β-DHA to
maintain the equilibrium unbound in plasma according to Le
Chatelier’s principle and increase the overall ratio of α to β-
DHA in plasma.
Single-point computations based on the in vacuo optimized
geometries of α- and β-DHA predict β-DHA to be more stable
in the gas phase, in water, in 1-octanol, and in olive oil. To test
the effect of geometrical relaxation in solution and thermal
enthalpies and entropies on relative stability, α- and β-DHA
geometries were optimized in each solvent and frequency
calculations performed in order to identify a minimum in
energy with all positive real vibrational frequencies and to yield
thermal corrections to enthalpy as well as entropy in each
solvent. The thermally corrected results which included
entropic effects correctly predicted the greater thermodynamic
stability of α-DHA in water with ΔGβ→αo = −0.344 kJ mol−1,
ΔHβ→αo = 0.869 kJ mol−1, and ΔSβ→αo = 4.07 J mol−1 K−1 at
298.15 K. The greater entropy at 298.15 K of α-DHA in water
than β-DHA outweighs the more negative enthalpy of β-DHA,
which is not completely overcome by the fact that α-DHA is
more polar. These computations also give heat capacities, CV,
and with them ΔGβ→αo , ΔHβ→αo , and ΔSβ→αo can be
approximated at 310.15 K yielding ΔGβ→αo = −0.393 kJ
mol−1, ΔHβ→αo = 0.880 kJ mol−1, and ΔSβ→αo = 4.103 J mol−1
K−1. The Boltzmann population of α-DHA in water at 310.15
K is predicted to be 54% giving α-DHA/β-DHA ratio of 1.17,
correctly favoring but also underestimating the apparent
greater relative stability of α-DHA in an aqueous environment.
The greater ratio of α- to β-DHA in plasma may also be
increased by stronger binding of α-DHA to α1-acid
glycoprotein as discussed in the previous paragraph. Similar
computations with 1-octanol and olive oil as the solvents show
greater computed entropy of α-DHA than β-DHA in water
compared to these other solvents, which is due to low-
frequency vibrations involving the −OH group and DHA fused
ring systems and lower computed enthalpy presumably due to
stronger dipole−dipole interactions with the greater polarity of
α-DHA. The difference in predicted entropy is less in 1-
octanol and in olive oil, ΔGβ→αo = 2.83, ΔHβ→αo = 3.76 kJ
mol−1, ΔSβ→αo = 3.13 J mol−1 K−1, in 1-octanol and ΔGβ→αo =
5.12, ΔHβ→αo = 5.87 kJ mol−1 and ΔSβ→αo = 2.45 J mol−1 K−1 in
olive oil. β-DHA is predicted to be more stable than α-DHA in
octanol and olive oil at 310.15 K.
Quinine and quinidine, also diastereomers, show difference
in antimalarial activity; quinidine shows twice the antimalarial
activity as quinine against P. falciparum.19 Inspection of Figure
5 reveals that they differ from being mirror images only in the
position of the quinuclidine vinyl group. Warhurst et al. (2003)
report log Kow values of 3.17 and 2.84 for quinine and
quinidine, respectively, but also cite Tsai et al. (1993) as giving
2.64 for quinine and 2.88 for quinidine. Our computations
agree with the latter predicting log Kow to be greater for
quinidine than for quinine. The shorter terminal elimination
half-life for quinidine, that is, 6.09 h compared to 12.34 h for
quinine then does not follow the general trend of increased
elimination half-life with increased lipophilicity. The longer
elimination half-life of quinine can be explained by the greater
protein binding of quinine (85−95%) compared to quinidine
(70−80%).73 If quinidine is indeed less lipophilic than quinine,
it is interesting that it has less protein binding. Urien et al.
(1995) in their study of the binding of eight drugs to α1-acid
glycoprotein found that ΔGbind does not have a strong
correlation with physicochemical parameters including log
Kow.
75 On considering ΔHbind and TΔSbind independently, they
found strong linear relationships of each with log Poct‑hep = log
Kow − log Khw, where Khw is the heptane−water partition
coefficient.75 ΔHbind becomes more negative with increased log
Figure 8. β-arteether DFT-optimized geometry. C6-O2 endoperoxide
and C10-OEt bond dipoles point in opposite directions partially
cancelling the molecular dipole moment. Atom numbering is the same
as in Figure 2.
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Poct‑hep and −TΔSbind less negative.75 The log Poct‑hep parameter
is a measure of dipole−dipole interaction between the solute
and octanol.75 The greater protein binding of quinine
compared to quinidine may be due to greater dipole moment,
that is 2.74 D for quinine compared to 2.46 D for quinidine
both in vacuo according to DFT. The computed log Poct‑hep
values also show the same trend, log Poct‑hep = 2.74 for quinine
and 2.46 for quinidine, coincidentally the same magnitudes as
their dipole moments. This is for the most stable conformer of
each which is also the most lipophilic. Given that quinine and
quinidine have nearly equal % β-haemitin inhibition, perhaps
quinidine’s greater antimalarial activity is due to its greater
lipophilicity leading to better penetration through the
erythrocyte cell membrane.19
Given the structural similarity between quinine and
quinidine, the differences in their properties are quite
interesting. Although one might expect the difference in
position of the quinuclidine vinyl group to cause differences in
rotational accessibility of the conformers, Zaera et al. (2009)
found little difference in the energy and accessibility of
cinchonidine and cinchonine conformers formed by rotations
around τ1 and τ2 (Table S2) and attribute solubility differences
between these and analogous cinchona compounds such as
quinidine and quinine to differences in vibrational entropy
mostly accounted for in the most stable conformer of each
compound and resulting from the change in center of mass
with different position of this vinyl substituent.20 The
difference in computed entropies they found showed agree-
ment with the temperature dependence of their experimentally
determined solubilities. Hoping to clarify the relative lip-
ophilicities of quinine and quinidine and to test the effects of
solvent specific geometry relaxation in each solvent and
differences in entropy and thermally corrected enthalpy,
quinine and quinidine geometries were optimized in water,
1-octanol, and olive oil and vibrational frequency analysis was
performed, confirming that a minimum in energy had been
found and yielding thermally corrected free energies,
enthalpies, entropies, and heat capacities at 298.15 K and
allowing those at 310.15 K to be predicted based on the
computed heat capacities. Results are given in Table 8.
The increase in entropy for quinidine going from water to 1-
octanol or olive oil while the transfer entropy of quinine is
negative is interesting and results from differences in
vibrational entropy in each solvent. The predicted effects at
298.15 and 310.15 K do not change the trend in lipophilicity.
With the effects of thermal enthalpies and entropies included,
both compounds are predicted to increase relative solubility in
water with increased temperature. Quinidine is still predicted
to be more lipophilic according to its more positive log Kow
and log Kvow values presented in Table 8.
Estimates of Terminal Elimination Half-Life. The
strong linear relationships found between log Kow and terminal
elimination half-life indicate the close relationship between
terminal t1/2 and relative thermodynamic stability in octanol or
olive oil compared to water, ΔGowo or ΔGvowo , for drugs that
trend together. Assuming similar plasma protein binding, rates
of metabolism, and relationships between distribution volume
and clearance for structurally similar drugs, these linear
relationships allow estimation of terminal elimination half-life
for experimental antimalarial drugs. As mentioned above, the
predominant DHA diastereomer in plasma was found to be α-
DHA.76 The DHA terminal half-life of 1.86 h given by Jitamala
et al. (2015)55 may reflect primarily the properties of α-DHA
and the predicted β-DHA half-life of 6 h may be of interest.
The smaller dipole moment and greater lipophilicity of β-DHA
may allow it easier penetration through the erythrocyte cell
membrane and greater antimalarial activity at the same time as
greater neurotoxicity. The predicted higher log Kow for β-
arteether than α-arteether matches β-arteether’s longer
terminal elimination half-life.
Avery et al. (2002) report terminal half-life in rats of Avery-
17 to be 73 min and that for Avery-14 to be less than this.12
Using log Kow = 5.69 from Table 3 and t1/2 = 1.22 h in eq 6
from Sarver et al. (1997)39 predicts a half-life of 5.72 h in
humans, which is surprisingly low, given the alkyl/aryl
substitution of these compounds and their high lipophilicity.
An abnormally low terminal elimination half-life could be
explained based on abnormally low volume of distribution,
Vd,ss,u. Avery et al. suggest that the lower apparent terminal
half-life of Avery-14 compared to Avery-17 may be due to
structural features of these compounds but also suggest that
the cause may be lower plasma concentrations for Avery-14
that reflect a distribution phase rather than a true terminal
phase.12 Computed dipole moments for Avery-14 and Avery-
17 are 4.41 and 4.86 D, respectively. Perhaps analogous to
quine and quinidine, Avery-17 has greater α1-acid glycoprotein
binding and longer terminal t1/2 compared to Avery-14 which
is more lipophilic. The greater potency of Avery-17, according
to our optimized geometries may be explained by a slightly
more obstructed endoperoxide group in Avery-14. The results
here suggest that if factors determining pharmacokinetics for
Avery-14 and Avery-17 are similar to other artemisinin drugs,
they have considerably longer terminal elimination half-life.
Avery-14 and Avery-17 are predicted to be highly lipophilic in
agreement with their large predicted log Kow values given in
Table 3. Avery et al. note that these compounds have high
potency but low bioavailability due to poor solubility. The
predicted terminal elimination half-lives of 48 and 45 h,
respectively, for Avery-14 and Avery-17, if accurate, may be in
an appropriate range to counter the altered life cycle of
resistant strains and perhaps would be less likely to trigger
Table 8. Transfer Entropies (J mol−1 K−1), Enthalpies (kJ mol−1), Heat Capacities (kJ mol−1 K−1), log Kow, and log Kvow of
Quinine and Quinidine at 298.15 Ka
T = 298.15 K ΔSowo ΔSvowo ΔHowo ΔHvowo ΔCv,owo ΔCv,vowo log Kow log Kvow
quinine −0.623 −5.028 −10.197 1.376 −0.385 −0.946 1.75 −0.503
quinidine 1.331 7.242 −10.610 0.635 −0.2.01 −0.121 1.94 0.267
T = 310.15 K ΔSowo ΔSvowo ΔHowo ΔHvowo ΔGowo ΔGvowo log Kow log Kvow
quinine −0.639 −5.058 −10.202 −1.364 −10.004 2.933 1.68 −0.494
quinidine 1.581 7.238 −10.612 0.634 −11.103 −1.611 1.87 0.271
aTransfer entropies (J mol−1 K−1), enthalpies (kJ mol−1), Gibbs free energies (kJ mol−1 K−1), and log Kow and log Kvow of quinine and quinidine at
310.15 K.
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resistance and neurotoxicity if they do not have DHA as an
active metabolite.
F1-DHA is found to have higher lipophilicity than F2-DHA
in agreement with their log Koct:Ringer but perhaps the estimated
log Kow values in Table 3 allow them to be considered in a
consistent context with other antimalarial drugs. The C10
fluoroalkyl group of F1-DHA presents an obstacle to transfer
across the intestinal lining, so the estimated terminal
elimination half-life given in Table 6 is likely not of much
interest. The predicted terminal elimination half-life of F2-
DHA, which is 10 h, is similar to those for DHA, artemether,
and arteether, drugs with greater possible neurotoxicity and
perhaps greater vulnerability to artemisinin-resistant malaria
because their active metabolite, DHA, may trigger the dormant
ring stage.5
■ SUMMARY AND CONCLUSIONS
The results here show that quantum chemical log Kow values
from DFT with the SMD implicit solvent model have a strong
linear relationship with the terminal elimination half-life for
drugs used in antimalarial ACT therapies and experimental
antimalarial drugs. This relationship follows a simple
pharmacokinetic model, and the results modeling olive oil as
a solvent match the predicted relationship between the slope
and intercept, which is perhaps an indication that olive oil as a
biological fat is more appropriate than 1-octanol in comparison
to these in vivo drug properties. The predicted log Kow values
for 21 antimalarial drugs based on computed water to 1-
octanol underestimate the relative stability in 1-octanol by a
mean of value of 2.3 kJ mol−1 and show a mean unsigned error
of 3.7 kJ mol−1, which is in good agreement with the literature
mean unsigned error values for compounds with similar
functionalities. Errors are larger for larger molecules with more
rotatable bonds consistent with the work of Kolaŕ ̌ et al.
(2013).21 In plots of log Kow versus terminal t1/2, artemisinin
and amino alcohol-based drugs were found to trend together
and 4-aminoquinoline compounds are found to trend with
mefloquine and pyronaridine, consistent with the protein
binding of these different families of compounds. The linear fit
with olive oil as the modeled solvent allows terminal
elimination half-lives to be estimated for β-DHA and five
experimental antimalarial drugs. An advantage of the method-
ology used here is that the physical properties of compounds
with subtle but important geometric differences can be
distinguished as demonstrated by the three sets of diaster-
eomers studied. Computed differences between α and β-
arteether correlate with their different t1/2 and allow for
interpretation of their slightly different antimalarial activity.
Computed lipophilicities for α and β-DHA allow experimen-
tally determined log Kow to be assigned for them. The α
diastereomer of DHA is found to be favored in aqueous media,
and this is understood in terms of its greater entropy in water.
Solubilities of quinine and quinidine are also found to be
sensitive thermal effects of thermal enthalpy and entropy in
different solvents. The experimental antimalarial drugs studied
in this work were previously designed for longer t1/2 and lower
neurotoxicity. It is suggested based on their estimated terminal
elimination half-lives that their properties or properties of
similar drugs may also be conducive to addressing the problem
of ACT-resistant strains based on the resistant strains’ altered
developmental stages.
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